RxDoctor Payments DataLook up a doctor →

Vinay Shah, MD

Retina Specialist · Oklahoma City, OKNPI 1013951409

Payments from drug & device makers

$142,752in general payments, 2019–2025

Across 94 payments — averaging $1518.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$48K
  • Bausch & Lomb Americas Inc.$40K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$35K
  • Glaukos Corporation$16K
  • Carl Zeiss Meditec, Inc.$750
  • Regeneron Healthcare Solutions, Inc.$367
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$16,33317%
  • Speaking & faculty fees$75,75080%
  • Food & beverage$2,6123%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,443,226
Medicare patients
1,233
Services billed
51,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate128$6,907
Alphagan PBrimonidine Tartrate13$3,931
Brimonidine Tartrate40$3,519
Ofloxacin119$2,096
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat68$1,171
ErythromycinErythromycin Base59$702
Ketorolac Tromethamine23$451
Atropine Sulfate12$448
Latanoprost40$335
Timolol Maleate32$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P$213$3,93113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other retina specialist in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →